Literature DB >> 22356805

Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.

Stephanie L Rellick1, Debbie Piktel, Cheryl Walton, Brett Hall, William Petros, James E Fortney, Marieta Gencheva, Jim Denvir, Gerald Hobbs, Michael Craig, Laura F Gibson.   

Abstract

Bone marrow stromal cells (BMSC) and osteoblasts are critical components of the microenvironment that support hematopoietic recovery following bone marrow transplantation. Aggressive chemotherapy not only affects tumor cells, but also influences additional structural and functional components of the microenvironment. Successful reconstitution of hematopoiesis following stem cell or bone marrow transplantation after aggressive chemotherapy is dependent upon components of the microenvironment maintaining their supportive function. This includes secretion of soluble factors and expression of cellular adhesion molecules that impact on development of hematopoietic cells. In the current study, we investigated the effects of chemotherapy treatment on BMSC and human osteoblast (HOB) expression of interleukin-6 (IL-6) as one regulatory factor. IL-6 is a pleiotropic cytokine which has diverse effects on hematopoietic cell development. In the current study we demonstrate that exposure of BMSC or HOB to melphalan leads to decreases in IL-6 protein expression. Decreased IL-6 protein is the most pronounced following melphalan exposure compared to several other chemotherapeutic agents tested. We also observed that melphalan decreased IL-6 mRNA in both BMSC and HOB. Finally, using a model of BMSC or HOB co-cultured with myeloma cells exposed to melphalan, we observed that IL-6 protein was also decreased, consistent with treatment of adherent cells alone. Collectively, these observations are of dual significance. First, suggesting that chemotherapy induced IL-6 deficits in the bone marrow occur which may result in defective hematopoietic support of early progenitor cells. In contrast, the decrease in IL-6 protein may be a beneficial mechanism by which melphalan acts as a valuable therapeutic agent for treatment of multiple myeloma, where IL-6 present in the bone marrow acts as a proliferative factor and contributes to disease progression. Taken together, these data emphasize the responsiveness of the microenvironment to diverse stress that is important to consider in therapeutic settings.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356805      PMCID: PMC3319530          DOI: 10.1016/j.cyto.2012.01.012

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  41 in total

1.  Bone marrow subendosteal microenvironment harbours functionally distinct haemosupportive stromal cell populations.

Authors:  Alex Balduino; Sandra P Hurtado; Priscilla Frazão; Christina M Takiya; Leandro M Alves; Luiz-Eurico Nasciutti; Márcia C El-Cheikh; Radovan Borojevic
Journal:  Cell Tissue Res       Date:  2004-12-01       Impact factor: 5.249

Review 2.  The stem cell niches in bone.

Authors:  Tong Yin; Linheng Li
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

Review 3.  Understanding hematopoietic stem-cell microenvironments.

Authors:  Zhixing Li; Linheng Li
Journal:  Trends Biochem Sci       Date:  2006-09-05       Impact factor: 13.807

Review 4.  Beyond angiogenesis: the role of endothelium in the bone marrow vascular niche.

Authors:  Angela Colmone; Dorothy A Sipkins
Journal:  Transl Res       Date:  2007-10-04       Impact factor: 7.012

5.  A role for niches in hematopoietic cell development.

Authors:  Beate Heissig; Yuichi Ohki; Yayoi Sato; Shahin Rafii; Zena Werb; Koichi Hattori
Journal:  Hematology       Date:  2005-06       Impact factor: 2.269

6.  Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function.

Authors:  Brahmananda R Chitteti; Ying-Hua Cheng; Bradley Poteat; Sonia Rodriguez-Rodriguez; W Scott Goebel; Nadia Carlesso; Melissa A Kacena; Edward F Srour
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients.

Authors:  M Galotto; G Berisso; L Delfino; M Podesta; L Ottaggio; S Dallorso; C Dufour; G B Ferrara; A Abbondandolo; G Dini; A Bacigalupo; R Cancedda; R Quarto
Journal:  Exp Hematol       Date:  1999-09       Impact factor: 3.084

8.  Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.

Authors:  Alexandros Spyridonidis; Tisa Küttler; Ralph Wäsch; Eva Samek; Miguel Waterhouse; Dirk Behringer; Hartmut Bertz; Jürgen Finke
Journal:  Stem Cells Dev       Date:  2005-04       Impact factor: 3.272

9.  Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Authors:  John Kuruvilla; John D Shepherd; Heather J Sutherland; Thomas J Nevill; Janet Nitta; Aulan Le; Donna L Forrest; Donna E Hogge; Julye C Lavoie; Stephen H Nantel; Cynthia L Toze; Clayton A Smith; Micheal J Barnett; Kevín W Song
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-29       Impact factor: 5.742

10.  High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Charalampia Kyriakou; Carmen Canals; Anthony Goldstone; Dolores Caballero; Bernd Metzner; Guido Kobbe; Hans-Jochem Kolb; Joachim Kienast; Peter Reimer; Jurgen Finke; Gunnar Oberg; Ann Hunter; Niklas Theorin; Anna Sureda; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

View more
  4 in total

1.  Clonality in context: hematopoietic clones in their marrow environment.

Authors:  James N Cooper; Neal S Young
Journal:  Blood       Date:  2017-10-18       Impact factor: 22.113

2.  A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.

Authors:  Christina Mark; Jay Warrick; Natalie S Callander; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

3.  Differential role of gp130-dependent STAT and Ras signalling for haematopoiesis following bone-marrow transplantation.

Authors:  Daniela C Kroy; Lisa Hebing; Leif E Sander; Nikolaus Gassler; Stephanie Erschfeld; Sara Sackett; Oliver Galm; Christian Trautwein; Konrad L Streetz
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

4.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma.

Authors:  Armando Sardi; Carlos A Muñoz-Zuluaga; Michelle Sittig; Teresa Diaz-Montes
Journal:  Clin Case Rep       Date:  2018-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.